Laurent Goux

#News: Bayer and Evotec have updated the focus of their strategic collaboration to develop #precisiontreatments for #cardiovasculardiseases (CVDs). Financial terms were not disclosed.   The collaboration aims to identify and validate #noveltargets, with the goal of building a portfolio of precision #cardiologytherapeutics by leveraging #Evotec's disease modelling capabilities using human #inducedpluripotentstemcells (iPSCs). #iPSCs provide unique opportunities to identify new disease mechanisms and pathways for novel treatments. Under the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality technology platforms.   Bayer and Evotec will share responsibilities during the preclinical development of potential clinical candidates. Bayer will be responsible for any subsequent clinical development and commercialization.   “This development takes our long-standing collaboration with Evotec to a new level, and has the added benefit of lessons learned from working together the past 12 years,” said Juergen Eckhardt, M.D., Head of Business Development & Licensing at Bayer’s Pharmaceuticals Division. “We remain committed to develop innovative therapies for patients in need and to tackle the high burden of cardiovascular disease.”
 Read more from Contract Pharma 👇🏼

4

Sanofi Invests €1 Billion to Boost Drug Manufacturing in #France Paris-based French #drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new #bioproduction capacity. The new #investment is expected to create more than 500 jobs and significantly strengthen France's ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the #Covid-19 pandemic to over €3.5 billion. In Vitry-sur-Seine, Sanofi wants to invest €1 billion to build a new facility that will double the site's #monoclonal antibody production capacity, where several biologics in development amongst Sanofi’s pipeline of drugs for the treatment of chronic obstructive pulmonary disorder (COPD), #asthma, multiple sclerosis or type 1 #diabetes, could be produced. At the Le Trait site in Normandy, Sanofi plans to invest €100 million to expand the capacity for #biologics formulation, filling, device assembly and packaging, supporting the launch of future biologics and vaccines, as well as and the further growth of existing biologics production. Read more on #CMI online: https://lnkd.in/eaDSXr-k

3

What a great and highly interesting panel discussion about a "hot" topic 😉. Radioligand therapies panel discussion on the 2nd day of the #SwissBiotechDay. Thanks to the organisers to set this up! #Radioligandtherapies #basel #SwissBiotech

11

The overall picture of the Swiss biotech industry is quite positive. The Swiss Biotech Report recently published provides an analysis of the 2023 biotech funding as well as other key ratios and statistics: https://lnkd.in/dGSvh2d With Swiss Biotech Association https://lnkd.in/dAtS7hyU

152

A new study in the European Heart Journal raises alarm about the safety of #xylitol, which is a well-known ingredient in gum and mints, used to prevent poor oral health. As reported, xylitol increases platelet reactivity, is thrombolytic, and is associated with major adverse cardiovascular events. https://lnkd.in/ghzjjeFt This warning is similar to that issued about fluoridation of the water which is increasingly considered to have neuro-degenerative effects, particularly early in life. More studies about the risks of xylitol and fluoride are obviously needed. But preventive dentistry is now cautious about which way to turn. #Prevora has an exemplary safety record over many years, has multiple drug approvals and, as a professional treatment, is selective in its dosing and monitoring.

7

2 Kommentare

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/4MBLGy. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

7

The continuous biomanufacturing process has very high yields equivalent to about 30 g/L compared to titers for batch fed single use bioreactors or bags.

1

📈 GRIP-Pharma brings together the dynamic community of French-speaking pharmas and biotechs in Switzerland. Proud partners of the Swiss Biotech Association, we're thrilled to share the insights from the latest SWISS BIOTECH REPORT 2024. Dive into the report to uncover the newest trends and statistics shaping our industry! https://lnkd.in/gfkz7FH #GRIPPharma #SwissBiotech #Pharma #Biotech #IndustryInsights.

5

Are you joining us for this roundtable discussion at #ISCT2024 next week on how to better integrate sustainable processes into #cellandgenetherapy applications?

6

1 Kommentar

Hello Rare Diseases Community We mark #FabryAwarenessMonth in April, an important milestone for the Fabry community. For those unfamiliar with the condition, Fabry is a rare disease that can impact many parts of the body including the kidneys, heart, brain and skin. At Sanofi, we believe in the power of knowledge, compassion, and collective action to make a meaningful impact on rare diseases like Fabry. Part of our mission is rooted in pursuing better care through early diagnosis, which plays a crucial role in managing Fabry disease, particularly in women. Women with Fabry may present with variable symptoms, leading to delays in treatment or misdiagnoses. By continuing to research Fabry disease and raising awareness among healthcare providers, we can facilitate early detection and access to suitable care. One such way we contribute to advancing understanding is through our Fabry Registry. Established in 2001, this registry tracks patient journeys, offering valuable insights into the disease's impact over time and its link to sex and genetics. Hear more about the diagnosis journey of the women in the Hill family in this video.   Help us to spread awareness, ignite conversations, and amplify the impact of Fabry disease this month. Make sure to follow along on Sanofi’s corporate channels to learn more about how to get involved. 

127

🌟🌟🌟 "Big news in oncology! Novartis teams up with Arvinas to advance an oral protein degrader for prostate cancer, investing $150M upfront and up to $1.01B in milestones. Additionally, Novartis initiates a $2.9B tender offer for MorphoSys. Exciting times ahead in cancer treatment! 🌟🌟🌟 #Novartis #Arvinas #MorphoSys #ProstateCancer #Oncology" Follow us for more.

4

Memo Therapeutics or “MTx” has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. The new funding will be used to bolster the clinical advancement of MTx’s lead asset, AntiBKV for kidney transplant patients with a BK virus infection. This infection can lead to nephropathy, loss of kidney function, as well as organ failure and rejection. The disease represents a potential market in excess of $1 billion. New investors Ysios Capital and Kurma Partners participated in the extension round, joining existing Series C round investors including Pureos Bioventures, Swisscanto, Verve Ventures and Redalpine. Erik van den Berg Christoph Esslinger Lars Spenger Memo Therapeutics AG Thomas Harth Ysios Capital Hadrien Bouchez Kurma Partners Veronica Gambillara Fonck Pureos Bioventures #viralinfection #kidney #transplant #nephropathy #clinicaltrials https://lnkd.in/e7HwNkiP

7

This month my colleagues are diving into the challenges in transfers of fermentation processes from the laboratory to industrial scales, discussing the risks may arise during the biotechnology go-to market journey and how Arxada may help to mitigate them. #Arxada #CDMO #Fermentation

17

Our CEO, Hubertus von Baumbach, underscores in today's edition of Handelsblatt the critical role our votes play in shaping the future of Europe, especially amidst the current challenges. As a company deeply invested in life sciences and pharmaceutical R&D, we echo his call for strengthening European competitiveness in these fields. Let's use our votes to build a stronger, more innovative Europe. Learn more here: https://lnkd.in/enbXBV4n #EuropeanElections #VoteForEurope

249

4 Kommentare

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/o2tybU. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

24